Topic · page 6 of 47

Lupus & antiphospholipid syndrome

Systemic and cutaneous lupus erythematosus, lupus nephritis, neuropsychiatric lupus, disease activity, remission and low disease activity, damage, antimalarials and targeted treatment; antiphospholipid antibodies and antiphospholipid syndrome, thrombotic and obstetric

Briefs 201–240 of 1,848 placed here, newest publication first

Briefs in Lupus & antiphospholipid syndrome

Newest publication first

Lupus Sci Med16 Jun 2026
Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study
Cross-sectional study
Rheumatology (Oxford)16 Jun 2026
Risk of chronic kidney disease in newly diagnosed SLE with preserved renal function: a national study
Cohort study
Lupus15 Jun 2026
Skin involvement in the catastrophic antiphospholipid syndrome: A review from CAPS registry
Cross-sectional study
Rheumatology (Oxford)13 Jun 2026
Prevalence and prognostic value of activated protein C resistance and anti–protein C antibodies in patients with aPLs: an APS ACTION Registry study
Cohort study
Lupus Sci Med12 Jun 2026
Systemic Lupus International Collaborating Clinics Frailty Index predicts mortality in systemic lupus erythematosus patients: data from the Almenara Lupus Cohort
Cohort study
Lupus11 Jun 2026
Outcomes of systemic lupus erythematosus hospitalisations in Qatar: Insights from a multinational tertiary centre experience
Cohort study
Lupus10 Jun 2026
Comparative performance of lupus disease-activity indices during pregnancy to predict adverse obstetric outcomes: A colombian SLE cohort
Cohort study
Arthritis Care Res (Hoboken)9 Jun 2026
Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis
Cohort study
Semin Arthritis Rheum9 Jun 2026
Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis
Meta-analysis
Lupus5 Jun 2026
Kidney outcomes in pure membranous versus proliferative lupus nephritis: A 14-year Latin American cohort study
Cohort study
Arthritis Rheumatol3 Jun 2026
Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation
Cohort study
Lupus3 Jun 2026
Unveiling the role of TLR9 promoter variants in susceptibility and clinical features of systemic lupus erythematosus
Case-control study
Lupus3 Jun 2026
A quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic
Research article
Lupus Sci Med2 Jun 2026
Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study
Cross-sectional study
Semin Arthritis Rheum2 Jun 2026
Spanish multicenter registry of belimumab in systemic lupus erythematosus: Data from daily clinical practice
Cohort study
Arthritis Rheumatol2 Jun 2026
T Cell Plasticity in Systemic Lupus Erythematosus Revealed by Large‐Scale T Cell Receptor Repertoire and Transcriptome Studies
Mechanistic study
Lupus1 Jun 2026
Comparative study of adverse drug reactions associated with anifrolumab and belimumab for the treatment of systemic lupus erythematosus
Cohort study
Lancet29 May 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
Randomized controlled trial
Lupus Sci Med29 May 2026
Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation
Diagnostic or prognostic study
Lupus Sci Med27 May 2026
Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis
Cohort study
Joint Bone Spine26 May 2026
Type I Interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus
Cohort study
Rheumatology (Oxford)25 May 2026
Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study
Cohort study
Lupus Sci Med20 May 2026
Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial
Trial design
Arthritis Care Res (Hoboken)20 May 2026
Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus
Cross-sectional study
Lupus Sci Med18 May 2026
Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnancies
Cohort study
Arthritis Rheumatol18 May 2026
A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ ‐ SAFE Study
Research article
Arthritis Care Res (Hoboken)18 May 2026
Association of Vaccination With COVID Outcomes in Pregnant People With Autoimmune Diseases: A Retrospective National Cohort Analysis
Cohort study
Arthritis Care Res (Hoboken)18 May 2026
Voclosporin and Changes in Blood Pressure: An Analysis of Real‐World Data
Cohort study
Lupus Sci Med17 May 2026
Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan
Cohort study
Arthritis Care Res (Hoboken)15 May 2026
Artificial Intelligence–Based Online Symptom Assessment Tools for Systemic Lupus Erythematosus Diagnosis: Patient Perspectives
Research article
Arthritis Res Ther14 May 2026
Aberrant sphingosine-1-phosphate receptor 1 expression on activated naive B cells associated with disease activity and lupus nephritis in systemic lupus erythematosus
Mechanistic study
RMD Open13 May 2026
Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study
Cohort study
Ann Rheum Dis12 May 2026
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial
Secondary analysis
Arthritis Care Res (Hoboken)12 May 2026
Discordance Between Systemic Lupus Erythematosus Disease Activity Index Domain Weights and Their Association With Organ Damage Accrual
Cohort study
Arthritis Res Ther11 May 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study
Cohort study
Rheumatology (Oxford)11 May 2026
Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study
Cohort study
Arthritis Care Res (Hoboken)10 May 2026
Mucocutaneous Disease Activity and Damage Accrual in Systemic Lupus Erythematosus: Analyses From the Asia‐Pacific Lupus Collaboration Longitudinal Cohort Study
Cohort study
Lancet9 May 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
Randomized controlled trial
Rheumatology (Oxford)8 May 2026
Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability
Cohort study
Lancet Rheumatol7 May 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial
Randomized controlled trial

All 1,848 Briefs in ExploreShowing Briefs 201–240 of 1,848, newest first